Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy A Meta-analysis

被引:76
|
作者
Al-Khatib, Sana M. [1 ]
Fonarow, Gregg C. [2 ]
Joglar, Jose A. [3 ]
Inoue, Lurdes Y. T. [4 ]
Mark, Daniel B. [1 ]
Lee, Kerry L. [5 ]
Kadish, Alan [6 ]
Bardy, Gust [7 ]
Sanders, Gillian D. [8 ]
机构
[1] Duke Univ, Med Ctr, Div Cardiol, Duke Clin Res Inst, Durham, NC 27710 USA
[2] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA
[3] Univ Texas Southwestern, Div Cardiol, Dallas, TX USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[6] Northwestem Mem Hosp, Feinberg Sch Med, Div Cardiol, Chicago, IL USA
[7] Univ Washington, Div Cardiol, Seattle, WA 98195 USA
[8] Duke Univ, Med Ctr, Dept Clin Pharmacol, Duke Clin Res Inst, Durham, NC USA
关键词
SYSTOLIC HEART-FAILURE; DILATED CARDIOMYOPATHY;
D O I
10.1001/jamacardio.2017.0630
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Conflicting data have emerged on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden cardiac death (primary prevention ICDs) in patients with nonischemic cardiomyopathy. OBJECTIVE To investigate the association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiomyopathy. DATA SOURCES PubMed was searched from January 1, 2000, through October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy. Additional references were identified from bibliographies of pertinent articles and queries to experts in this field. STUDY SELECTION Inclusion criteria consisted of a randomized clinical trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with nonischemic cardiomyopathy. In addition, studies had to report on all-cause mortality during a follow-up period of at least 12 months and be published in English. The search yielded 10 studies, of which only 1 met the inclusion criteria. A search of bibliographies of pertinent articles and queries of experts in this field led to 3 additional studies. DATA EXTRACTION AND SYNTHESIS The PRISMA guidelines were used to abstract data and assess data quality and validity. Data were pooled using fixed-and random-effects models. MAIN OUTCOMES AND MEASURES The primary end pointwas all-cause mortality. Before data collection started, primary prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic cardiomyopathy. RESULTS Four randomized clinical trials met the selection criteria and included 1874 unique patients; 937 were in the ICD group and 937 in the control group. Pooling data from these trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95% CI, 0.61-0.93; P=.008; P=.87 for heterogeneity). CONCLUSIONS AND RELEVANCE Primary prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic cardiomyopathy. These findings support professional guidelines that recommend the use of ICDs in such patients.
引用
收藏
页码:685 / 688
页数:4
相关论文
共 50 条
  • [1] Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis
    Akel, Tamer
    Lafferty, James
    CARDIOVASCULAR THERAPEUTICS, 2017, 35 (03)
  • [2] Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials
    Stavrakis, Stavros
    Asad, Zain
    Reynolds, Dwight
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2017, 28 (06) : 659 - 665
  • [3] Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy A Systematic Review and Meta-analysis
    Kolodziejczak, Michalina
    Andreotti, Felicita
    Kowalewski, Mariusz
    Buffon, Antonino
    Ciccone, Marco Matteo
    Parati, Gianfranco
    Scicchitano, Pietro
    Uminska, Julia M.
    De Servi, Stefano
    Bliden, Kevin P.
    Kubica, Jacek
    Bortone, Alessandro
    Crea, Filippo
    Gurbel, Paul
    Navarese, Eliano P.
    ANNALS OF INTERNAL MEDICINE, 2017, 167 (02) : 103 - 111
  • [4] Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Cardiomyopathy
    Daubert, James P.
    Barnett, Adam S.
    JACC-HEART FAILURE, 2019, 7 (08) : 725 - 727
  • [5] Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy
    Littmann, Laszlo
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (03) : 233 - 233
  • [6] Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy RESPONSE
    Kolodziejczak, Michalina
    Andreotti, Felicita
    Navarese, Eliano Pio
    ANNALS OF INTERNAL MEDICINE, 2018, 168 (03) : 234 - 235
  • [7] Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis
    Jaiswal, Vikash
    Taha, Amira Mohamed
    Joshi, Amey
    Deb, Novonil
    Kanagala, Sai Gautham
    Nebuwa, Chikodili
    Ang, Song Peng
    Halder, Anupam
    Rajak, Kripa
    Jha, Mayank
    Harshakumar, Sreedevi Pallath
    Mattumpuram, Jishanth
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (02)
  • [8] Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy
    Shah, Rahman
    Sabghi, Roxanna
    Dennis, Mary
    JAMA CARDIOLOGY, 2017, 2 (11) : 1282 - 1283
  • [9] Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: Diminishing Returns With Advancing Age?
    Al-Khatib, Sana M.
    Pokorney, Sean D.
    CIRCULATION, 2017, 136 (19) : 1781 - 1783
  • [10] Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials
    Desai, AS
    Fang, JC
    Maisel, WH
    Baughman, KL
    CIRCULATION, 2004, 110 (17) : 625 - 625